Compare BridgeBio Pharma Inc (BBIO) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Weibo Corp — how do they compare? BridgeBio Pharma Inc trades at $82.29 (market cap $16.46B), while Weibo Corp trades at $7.82 (market cap $1.88B). The key difference: BridgeBio Pharma Inc is far larger — about 8.8× Weibo Corp's market cap, and Weibo Corp pays a 7.96% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | WB | |
|---|---|---|
Market Cap | $16.46B | $1.88B |
Sector | Health | Media |
52-Week High | $90.17 | $12.83 |
52-Week Low | $44.81 | $7.20 |
Enterprise Value | $18.02B | $1.16B |
Dividend Yield | — | 7.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Weibo (WB) trades at $7.67, down 0.65% on the day, with a bullish technical signal from moving averages and strong valuation metrics including a P/E of 5.37 and P/B of 0.49. The company reported $449.02M net income for 2025 with a 25.55% margin, though recent quarters saw EPS misses. A $0.61 dividend for H1-26 is scheduled, and cash flow trends show improvement in 2025. Analyst sentiment is mixed with 45% buy ratings.
The outlook balances deep value against competitive pressures. Upside is supported by low multiples and robust cash flow, but risks include user engagement challenges from rivals like Douyin and inconsistent earnings performance. The stock presents a value opportunity with income, yet requires monitoring of competitive and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
